Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma
Mary Cianfrocca(Northwestern University), Joseph A. Sparano(Tisch Cancer Institute), Jeannette Y. Lee(University of Arkansas at Little Rock), David M. Aboulafia(Virginia Mason Medical Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jamie Von Roenn(Northwestern University), Bruce J. Dezube(Xilio Therapeutics (United States)), Richard F. Ambinder(Johns Hopkins University), Anil Tulpule(University of Southern California)
Cited by 171
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
|JNCI Journal of the National Cancer Institute|2013|523